Ucb SA
XBRU:UCB

Watchlist Manager
Ucb SA Logo
Ucb SA
XBRU:UCB
Watchlist
Price: 242.2 EUR -2.42% Market Closed
Market Cap: 47.1B EUR

Gross Margin
Ucb SA

73.4%
Current
70%
Average
48.7%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
73.4%
=
Gross Profit
5B
/
Revenue
6.8B

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
BE
Ucb SA
XBRU:UCB
47.2B EUR
73%
US
Eli Lilly and Co
NYSE:LLY
939.9B USD
83%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
US
Johnson & Johnson
NYSE:JNJ
485.5B USD
68%
CH
Roche Holding AG
SIX:ROG
252.8B CHF
74%
UK
AstraZeneca PLC
LSE:AZN
210.6B GBP
82%
CH
Novartis AG
SIX:NOVN
206B CHF
76%
US
Merck & Co Inc
NYSE:MRK
239.1B USD
79%
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
82%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
68%
US
Pfizer Inc
NYSE:PFE
145.2B USD
75%
No Stocks Found

Ucb SA
Glance View

Market Cap
46B EUR
Industry
Pharmaceuticals

UCB SA, a Belgian multinational biopharmaceutical company, stands at the forefront of innovation in the medical field, committed to creating value by discovering new ways to treat severe diseases. Founded in 1928, UCB has transformed over the decades from its initial focus in chemicals to pioneering developments in advanced therapeutics targeting central nervous system disorders and immunology. Anchored by a robust research pipeline and a keen focus on rare diseases and specialty care, UCB has established a strong presence globally, reflecting its strategic pivot toward patient-centric approaches. With primary research facilities stationed in Braine-l'Alleud, Belgium, and Slough, UK, the company's scientific endeavors are bolstered by collaborations with research institutions worldwide, fostering an environment ripe for breakthrough discoveries. Financially, UCB's revenue streams are predominantly derived from its established portfolio of blockbuster drugs, such as Cimzia, Vimpat, and Keppra, which serve as critical lifelines for patients dealing with autoimmune diseases, epilepsy, and other chronic conditions. The company thrives on a dynamic business model that combines in-house scientific research with strategic partnerships and acquisitions to enhance its competitive edge. This synergy not only facilitates sustained growth in its core markets but also drives expansion into emerging ones, underscoring its global reach. By reinvesting substantial portions of its earnings into research and development, UCB ensures a steady pipeline of new products, thereby maintaining its stature in the highly competitive biopharmaceutical landscape. Through such strategic maneuvers, UCB aligns its operations with the overarching goal of delivering transformative therapies that improve the quality of life for patients around the world.

UCB Intrinsic Value
238.26 EUR
Overvaluation 2%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
73.4%
=
Gross Profit
5B
/
Revenue
6.8B
What is the Gross Margin of Ucb SA?

Based on Ucb SA's most recent financial statements, the company has Gross Margin of 73.4%.

Back to Top